New Blood Cancer Trial Shows 51% Reduction in Risk of Disease Progression or Death

Researchers and pharmaceutical companies have reported encouraging results from a late-stage clinical trial involving patients with newly diagnosed diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.

The study evaluated Epkinly in combination with standard treatment. According to the reported results, the combination significantly reduced the risk of disease progression or death compared with standard treatment alone. The reported reduction in risk was 51%.

The development is important because although treatment outcomes for aggressive blood cancers have improved, some patients still experience disease progression or relapse. New treatment combinations could potentially expand the number of patients who respond effectively to first-line therapy.

The companies reported that the combination was generally well tolerated, although detailed safety and efficacy data will be important for physicians and regulators to evaluate.

The results are from a clinical trial and do not mean that Epkinly is automatically the appropriate treatment for every lymphoma patient. Regulatory discussions and detailed clinical evaluation will determine how the findings could affect future treatment guidelines.